Marksans Pharma Ltd (NSE:MARK) witnessed a surge in its stock price on Tuesday following a positive regulatory development. The company’s wholly owned UK subsidiary, Relonchem Ltd, has secured Marketing Authorisation from the Medicines and Healthcare Products Regulatory Agency (MHRA) for Baclofen 10 mg Tablets. This approval strengthens Marksans Pharma’s presence in the UK market and reinforces its growing portfolio of pharmaceutical offerings.
Baclofen 10 mg Tablets are prescribed to relax specific muscles, easing spasms, cramping, and tightness primarily associated with multiple sclerosis or spinal injuries. The company officially announced this regulatory milestone via an exchange filing on March 19, underscoring its continued commitment to expanding its therapeutic range across global markets.
Strategic Expansion in the UK Market
Marksans Pharma, headquartered in Mumbai, specializes in research, manufacturing, and marketing of generic pharmaceutical formulations worldwide. The company operates manufacturing units in India, the USA, and the UK, all of which adhere to strict regulatory approvals from authorities such as the USFDA, UK MHRA, and Australian TGA.
This recent approval follows a similar achievement in February when Relonchem Ltd received MHRA authorization for Ibuprofen and Paracetamol 200 mg/500 mg Film-coated Tablets—widely used for pain relief and fever management. These back-to-back regulatory approvals indicate the company’s strategic focus on increasing its product footprint in key global markets, further strengthening its competitive edge.
What This Means for Investors
While this regulatory win is a positive catalyst for Marksans Pharma, a closer look at the company’s valuation offers a clearer picture for investors. According to InvestingPro’s fair value analysis, the intrinsic value of Marksans Pharma currently stands at INR 204.1 per share. With the stock’s current market price at INR 207, this reflects a marginal downside potential of 1.4%, suggesting that the stock is almost fairly valued at present.
Image Source: InvestingPro
Investors looking for lucrative entry points may consider waiting for a more attractive valuation gap before taking long positions. InvestingPro’s fair value feature eliminates the complexities of financial modeling by automating intrinsic value calculations with high precision. This tool enables investors to assess the overvaluation or undervaluation of stocks across global markets with ease.
For those keen on making informed investment decisions, InvestingPro offers comprehensive stock analysis tools, including fair value insights, historical performance data, and market comparisons. Currently, InvestingPro is offering discounts of up to 45%, making it an opportune moment to leverage its powerful analytics suite for smarter investment choices.
Read More: Ideas: A Deep Dive Into Billion-Dollar Portfolios
X (formerly, Twitter) - Aayush Khanna
LinkedIn - Aayush Khanna